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Abstract
AIM
To detect hyper-conserved regions in the hepatitis 
B virus (HBV) X gene (HBX ) 5’ region that could be 
candidates for gene therapy.
METHODS
The study included 27 chronic hepatitis B treatment-
naive patients in various clinical stages (from chronic 
infection to cirrhosis and hepatocellular carcinoma, both 
HBeAg-negative and HBeAg-positive), and infected with 
HBV genotypes A-F and H. In a serum sample from 
each patient with viremia > 3.5 log IU/mL, the HBX 
5’ end region [nucleotide (nt) 1255-1611] was PCR-
amplified and submitted to next-generation sequencing 
(NGS). We assessed genotype variants by phylogenetic 
analysis, and evaluated conservation of this region by 
calculating the information content of each nucleotide 
position in a multiple alignment of all unique sequences 
(haplotypes) obtained by NGS. Conservation at the HBx 
protein amino acid (aa) level was also analyzed.
RESULTS
NGS yielded 1333069 sequences from the 27 samples, 
with a median of 4578 sequences/sample (2487-9279, 
IQR 2817). In 14/27 patients (51.8%), phylogenetic 
analysis of viral nucleotide haplotypes showed a 
complex mixture of genotypic variants. Analysis of 
the information content in the haplotype multiple 
alignments detected 2 hyper-conserved nucleotide 
regions, one in the HBX upstream non-coding region (nt 
1255-1286) and the other in the 5’ end coding region 
(nt 1519-1603). This last region coded for a conserved 
amino acid region (aa 63-76) that partially overlaps a 
Kunitz-like domain.
CONCLUSION
Two hyper-conserved regions detected in the HBX 5’ end 
may be of value for targeted gene therapy, regardless 
of the patients’ clinical stage or HBV genotype.
Key words: Hepatitis B virus; Hepatitis B X gene; 
Hepatitis B X protein; Gene therapy; Next-generation 
sequencing; HBV conserved regions; Small interference 
RNA
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Hepatitis B virus (HBV) is not cured with classic 
treatments, and liver disease can progress by persistence 
and expression of covalently-closed circular DNA. Gene 
therapy with small interference RNA may be an effective 
approach to ensure inhibition of viral expression and 
disease progression, and hepatitis B virus X gene (HBX) 
transcripts could be optimal targets for this therapy. This 
study includes patients with different HBV genotypes 
and clinical stages to cover many clinical and virological 
situations. Using next-generation sequencing, we found 
two hyper-conserved HBX regions, candidates for small 
interference RNA therapy, which could enable pan-
genotypic inhibition of HBV expression, regardless of the 
patients’ disease status.
González C, Tabernero D, Cortese MF, Gregori J, Casillas R, 
Riveiro-Barciela M, Godoy C, Sopena S, Rando A, Yll M, 
Lopez-Martinez R, Quer J, Esteban R, Buti M, Rodríguez-Frías 
F. Detection of hyper-conserved regions in hepatitis B virus X 
gene potentially useful for gene therapy. World J Gastroenterol 
2018; 24(19): 2095-2107  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v24/i19/2095.htm  DOI: http://dx.doi.
org/10.3748/wjg.v24.i19.2095
INTRODUCTION
Despite the efficacy of preventive vaccines, an 
estimated 257 million people are living with chronic 
hepatitis B virus infection (CHB) and more than 880000 
people die each year of hepatitis B virus (HBV)-related 
complications such as cirrhosis and hepatocellular 
carcinoma (HCC) (WHO report, July 2017).
HBV is an enveloped DNA virus with partially double-
stranded circular DNA. HBV replication requires RNA 
intermediate and the activity of a reverse transcriptase. 
This implies a high probability that genetic mutations 
will occur, as the reverse transcriptase lacks 3’ to 
5’ proofreading activity, leading to a viral mutation 
rate of 10-4 to 10-5 substitutions/site/year, similar 
to that observed for RNA viruses[1]. Inter- and intra-
genotype recombination events can further increase 
HBV variability[2]. Hence, HBV circulates as a complex 
mixture of genetic variants, known as a quasispecies[3], 
that enables the virus to escape from the host’s 
immune system, antiviral treatment, and vaccination, 
thereby promoting progression to CHB. Furthermore, 
the mutational profile is closely associated with HBV 
genotype, and the genotype is associated with differing 
effectiveness of the treatments used and outcomes of 
the infection[4,5].
The main therapeutic approach for HBV infection 
is based on inhibition of the viral polymerase by the 
action of nucleotide analogues, whose goal is to 
improve the patients’ quality of life and prolong survival 
by preventing progression of the disease[6]. However, 
HBV cannot be completely eradicated with these drugs 
because the viral intermediate known as covalently 
closed circular DNA (cccDNA) can persist within the 
nucleus of HBV-infected liver cells. cccDNA interacts 
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with histone and non-histone proteins, including viral 
proteins such as the core and X protein (HBx), and 
forms a minichromosome that permits transcription of 
HBV genes[7], including pregenomic RNA, the precursor 
of de novo viral DNA genomes. Because cccDNA persists, 
it constitutes a viral reservoir that could promote 
reactivation of the infection after treatment interruption[8]. 
Within this challenging scenario, research has been 
aimed at deeply investigating the host-virus interactions 
to better understand the mechanisms that establish 
persistent HBV infection and to find new therapeutic 
targets that can cure it.
In this line, new treatment approaches are currently 
under development[9], with gene therapy being a 
promising option. Homing endonucleases, such as zinc-
finger endonucleases (ZFNs), transcription activator-
like effector nucleases (TALENs), and RNA-guided 
clustered regulatory interspaced short palindromic 
repeats associated with the Cas endonuclease family 
(CRISPR/Cas), can cleave selected sequences in 
cccDNA, resulting in disruption of the gene due to 
nonspecific DNA repair with consequent elimination of 
the viral minichromosome[10,11]. However, systematic 
random integration of the viral genome in the host 
genome could represent a strong limitation to this 
strategy. Indeed, the activity of this “molecular scissors”, 
although sequence-specific, could entail a potential risk 
of damage for the human genes close to the viral site of 
integration. 
Another promising gene therapy consists in silencing 
specific genes at the post-transcriptional level through 
a sequence-specific interaction between an mRNA 
target and small interfering RNA (siRNA)[12]. With this 
approach, various regions of the viral mRNA sequence 
can be targeted, including non-coding regions, without 
affecting the host DNA. Although these therapies show 
promise, the high variability of HBV and the association 
between this variability and the patients’ clinical 
outcome suggests that it may be important to find a 
highly conserved target to guarantee their efficacy. 
A good candidate for targeted gene therapy could 
be the HBx protein, encoded by the HBV X gene (HBX). 
This pleiotropic and multifunctional protein trans-
activates the expression of the viral genes. Together 
with the HBV core protein (HBc), HBx attaches to the 
cccDNA structure and is crucial for HBV replication[7]. In 
addition, this protein interacts with several cell signaling 
pathways and genes, thus affecting many cellular 
activities[13-15]. Due to its wide range of activity, HBx 
plays a key role in the pathogenesis of HBV infection 
and disease progression, and is strongly associated 
with HCC. Hence, it could be an optimal target for a 
hypothetical curative therapy for HBV infection.
The HBX gene, nucleotides (nt) 1374-1838, contains 
important regulatory elements[16,17]. The coded protein is 
comprised of 2 domains. The N-terminal domain [amino 
acid (aa) 1-50, encoded by the 5’ end of the gene] 
acts as negative regulator of the HBx transactivation 
function, which resides in the C-terminal domain 
(aa 51-154, encoded by the 3’ end). Interestingly, a 
significant presence of multiple variants with deletions 
and/or insertions (indels) has been found in the 3’ end 
of HBX[18-20]. Considering this variability, the 3’ coding 
region of the X gene would be ruled out as a possible 
therapeutic candidate[21]. However, the conservation at 5’ 
end of HBX and its potential for use as a gene therapy 
target remains unexplored. To silence HBX at the post-
transcriptional level, the non-coding region included in 
HBX transcripts, upstream of the coding region, should 
also be considered. The HBX gene is located near the 
co-terminal 3’ end; hence, all HBV mRNAs produced 
during the infection include this sequence (Figure 1). 
Consequently, by targeting HBX transcripts at the 
coding or non-coding level, interference with expression 
of all the viral proteins could be achieved.
The aim of this study was to determine the con-
servation of a region of the HBV genome encompassing 
the HBX 5’ coding region and upstream non-coding 
region (included in all HBV transcripts) in samples from 
HBV-infected patients in various clinical stages and with 
different viral genotypes. The ultimate objective was 
to find hyper-conserved regions that might be feasible 
targets for gene therapy, which could be used whatever 
the patient’s clinical status or HBV genotype. 
MATERIALS AND METHODS
Patients and samples
From a cohort of 46 well-characterized CHB patients 
attending the outpatient clinic of Vall d’Hebron University 
Hospital (Barcelona, Spain), we selected a group of 27 
patients in various clinical stages and with different viral 
genotypes. The samples included were 17 from HBeAg-
negative patients (3 with chronic infection and14 chronic 
hepatitis, 2 of them with cirrhosis and 1 with HCC), and 
10 from HBeAg positive (2 with chronic infection and 
8 with chronic hepatitis, 3 of them with cirrhosis and 2 
with HCC, characterized according to the latest EASL 
guidelines[6]), infected with several HBV genotypes: 5 A, 
1 B, 7 C, 8 D, 2 E, 3 F, 1 H (Table 1).
All 27 patients were treatment-naïve, tested nega-
tive for hepatitis D virus (HDV), hepatitis C virus (HCV), 
and human immunodeficiency virus (HIV), and had a 
serum sample with viremia levels > 3.5 logIU/mL, the 
sensitivity limit of the PCR to amplify the studied region 
(described below). The study was approved by the 
Ethics Committee of Vall d'Hebron Research Institute, 
and all patients signed a consent form to participate. 
Serological and virological determinations
HBV serological markers (HBsAg, HBeAg, and anti-HBe) 
and anti-HCV antibodies were tested using commercial 
chemiluminescent assays on a COBAS 8000 analyzer 
(Roche Diagnostics, Rotkreuz, Switzerland). Antibodies 
against HDV were tested using the HDV Ab kit (Dia.Pro 
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the universal adaptor M13 (underlined sequence) in 
their 5’ end (forward 5’-GTTGTAAAACGACGGCCAGT 
ATGCGTGGAACCTTTGTGGCT-3’ and reverse 
5’-CACAGGAAACAGCTATGACCATGGGCGTTCACGGT 
GGTCT-3’) using the following protocol: 95 ℃ for 2 
min, followed by 30 cycles of 95 ℃ for 15 s, 60 ℃ 
for 20 s, and 72 ℃ for 15 s, and finally, 72 ℃ for 3 
min. The second PCR round was performed using the 
primers: forward 5’-CGTATCGCCTCCCTCGCGCCATCAG-
MID-GTTGTAAAACGACGGCCAGT-3’ and reverse 
5’-CTATGCGCCTTGCCAGCCCGCTCAG-MID-CACAGGA 
AACAGCTATGACC-3’. These primers included the 2 
adaptors for the ultra-deep pyrosequencing system at 
their 5’ ends, followed by a unique identifier multiplex 
identifier sequence (MID), which enabled grouping the 
sequences for each sample/patient, and the same M13 
universal adaptor sequences as those used in the first 
PCR in the 3’ ends. This second amplification protocol 
comprised one denaturation step of 95 ℃ for 2 min, 
followed by 20 cycles of 95 ℃ for 15 s, 60 ℃ for 20 s, 
and 72 ℃ for 15 s, and finally, 72 ℃ for 3 min. All PCR 
steps were performed using high-fidelity Pfu Ultra II DNA 
polymerase (Stratagene, Agilent Technologies, Santa 
Clara, United States). The final PCR products (amplicons) 
Diagnostic Bioprobes, Sesto San Giovanni, Italy), and 
anti-HIV antibodies were tested by the Liaison XL murex 
HIV Ab/Ag kit (DiaSorin, Saluggia, Italy). HBV-DNA 
was quantified by real-time PCR with a detection limit 
of 10 IU/mL (COBAS 6800, Roche Diagnostics). HBV 
genotypes in the region of interest were determined by 
Sanger sequencing and by phylogenetic analysis with 
the same regions extracted from 102 full-length HBV 
genome sequences representative of HBV genotypes A 
to H, obtained from GenBank (Supplementary Table 1 
and Supplementary Figure 1). 
Amplification of the region of interest
In this study we analyzed a portion of the HBX gene 
encompassing HBX gene encompassed nt 1255 to nt 
1611, a region included in the 5’ end of all the viral 
transcripts. It covered a non-coding upstream region (nt 
1255-1373) and the 5’end of the HBX coding region (nts 
1374-1611), encoding aa 1 to 79 of HBx. 
HBV DNA was extracted from 500 µL of serum 
with the QIAamp UltraSens Virus Kit (QIAGEN, 
Hilden, Germany), according to the manufacturer’s 
instructions. Molecular amplification was performed by 
nested PCR. The first PCR round used primers carrying 
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Figure 1  Hepatitis B virus genome and transcripts. The figure shows the HBV genome (in grey), with the DR1 and DR2 (direct repeat) regions, necessary for viral 
DNA synthesis. The viral ORFs are highlighted with colored arrows, and nucleotide positions are reported. Wavy lines show the various HBV transcripts: the 3.5-kb 
transcript, corresponding to the pregenomic RNA, which is translated to the core and polymerase and later subjected to reverse-transcription in the viral capsid, or to 
the precore/core transcript, which is translated to the precore protein; the 2.4-kb and 2.1-kb transcripts, which are translated, respectively, to large and medium/small 
HBsAg); and the 0.7-kB transcript, which is translated to the HBx protein. The region analyzed in this study and its corresponding nt positions are indicated by red 
dashed lines. Note that the region of interest is included in all the viral transcripts. HBV: Hepatitis B virus; ORF: Open reading frame.
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were purified with Agencourt AMPure XP magnetic beads 
(Beckman Coulter, Beverly, United States). The quality of 
the purified products was verified with the Agilent 2200 
TapeStation System using the D1000 ScreenTape kit 
(Agilent Technologies, Waldbronn, Germany).
Next-generation sequencing and sequence quality 
control
Purified DNA from each sample was quantified using the 
Quant-iT PicoGreen dsDNA Assay Kit (Thermo Fisher 
Scientific - Life Technologies, Austin, United States), 
and a pool was formed in which each amplicon was 
adequately represented in the analysis. The pool was 
sequenced by next-generation sequencing (NGS) based 
on ultra-deep pyrosequencing (UDPS) on the GS-Junior 
or GS FLX platforms (454 Life sciences-Roche, Branford, 
United States), following the manufacturer’s protocol. 
The two platforms are reported to be interchangeable[22].
The sequences (reads) obtained after UDPS underwent 
an in-house bioinformatics filtering procedure, based 
on scripts developed in R language[23], as previously 
described by our group[22]. Briefly, the sequences were 
assigned to each patient (demultiplexed) according to 
their specific MID, and primers were trimmed. After 
a general quality filter step, reads with the same nt 
sequence were collapsed into haplotypes (unique 
sequences covering the full amplicon observed on the 
clean set of sequences). Only haplotypes common 
to the forward and reverse strands and present in 
abundances of at least 0.1% were accepted; their 
final frequencies were calculated as the sum of reads 
observed in each strand. Finally, haplotypes with 
abundances below 0.25% were excluded. 
To analyze the aa sequence of HBx, all individual nt 
haplotypes from each patient were translated into aa 
sequences in the HBX gene open reading frame (ORF), 
which was translated from frame 2. In the fragment 
analyzed (nt 1255-1611) this ORF expanded from nt 
1374 to 1611, encoding aa 1 to 79 of the HBx protein. 
The upstream sequence was not translated, as it 
corresponded to a non-coding region whose sequence 
is included in the HBX transcripts. Once translated, 
identical aa sequences were recollapsed into aa haplo-
types and their frequencies were updated.
Genotyping of the region haplotypes
The genotype of the nt haplotypes obtained by UDPS 
was determined by discriminant analysis with the same 
regions extracted from the 102 full-length patterns used 
for Sanger sequencing (Supplementary Table 1 and 
Supplementary Figure 1). We determined the maximum 
genetic distances between sequences from the same 
HBV genotype in this region and the minimum genetic 
distances between sequences from different genotypes, 
Table 1  Main clinical and virological characteristics of the hepatitis B virus infected patients enrolled
Patient Age Sex Origin Clinical stage HBeAg HBV DNA 
(log IU/mL)
ALT (IU/L) Genotype1
1 27 M Sub-Saharan Chronic hepatitis Negative 7.8 170 E
2 31 M Asian Chronic hepatitis Negative 6.6 103 C
3 51 M Caucasian Chronic hepatitis Negative 6.6 262 D
4 28 F Caucasian Chronic hepatitis Negative 7.9 126 D
5 47 F Caucasian Chronic hepatitis Negative 6.3 170 D
6 37 F Caucasian Chronic hepatitis Negative 4.5   53 D
7 37 M Caucasian Chronic hepatitis Negative 4.5   33 F
8 38 M Caucasian Chronic hepatitis Negative 5.0   29 D
9 46 M Caucasian Chronic hepatitis Negative 5.8   88 F
10 46 F Caucasian Chronic hepatitis Negative 5.3   23 H
11 71 F Caucasian Chronic hepatitis Negative 6.2   87 F
12 51 M Asian Chronic hepatitis Negative 5.7 435 C
13 52 M Caucasian Chronic infection Negative 4.4   18 A
14 40 F Caucasian Chronic infection Negative 4.2   29 D
15 33 M Asian Chronic infection Negative 4.3   25 D
16 63 M Hispanic Cirrhosis Negative 4.0   16 A
17 53 M Caucasian Cirrhosis/HCC Negative 3.7   36 A
18 35 M Sub-Saharan Chronic hepatitis Positive 5.7   36 E
19 37 M Caucasian Chronic hepatitis Positive 8.4   32 C
20 45 M Caucasian Chronic hepatitis Positive 5.6   35 A
21 29 F Asian Chronic hepatitis Positive 6.9 355 B
22 28 M Asian Chronic hepatitis Positive > 8.0 341 C
23 28 M Asian Chronic infection Positive 8.7   24 C
24 28 F Asian Chronic infection Positive 8.8   22 C
25 55 F Caucasian Cirrhosis Positive 5.4 73.9 A
26 82 F Caucasian Cirrhosis/HCC Positive 4.8   24 C
27 64 M Caucasian Cirrhosis/HCC Positive 6.3   45 D
1Genotype determined by Sanger sequencing of the X region (same region as was analyzed by next-generation sequencing). ALT: Alanine aminotransferase; 
HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; M: Male; F: Female; HBV: Hepatitis B virus.
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in order to set a sequence identity threshold: sequences 
with an identity above this threshold were clustered 
together. Genotyping of each cluster centroid was done 
by distance-based discriminant analysis (DB rule)[24,25], 
which takes into account the inter- and intra-class 
variability of all genotypes. Genetic distances were 
computed according to the Kimura-80 model[26]. 
Conservation analysis
Sequence conservation was determined by calculating 
the information content (IC) of each position in a 
multiple alignment of all the different sequences found 
in the patients. This analysis, based on Shannon’s 
uncertainty, was done for a multiple alignment of nt and 
aa sequences, and is defined as[27]:
where j stands for the j-th position in the alignment, 
i runs over the 4 nucleotides (or over the 20 aa), and 
pij is the frequency of the i-th nucleotide (or aa) in the 
j-th alignment position. IC ranges from 0, indicating 
maximum uncertainty or variability, to log2 4 (i.e., 2 
bits) for nt or log2 20 (i.e., 4.32 bits) for aa, indicating 
maximum information or conservation.
When considering variability in human genetics, a 
mutation is commonly considered fixed if it is found 
in at least 1% of the population[28]. However, in viral 
quasispecies, variants can be present at any abundance 
in a patient, and the limit for defining a fixed mutation 
has not yet been established. Taking that into account, 
we considered two scenarios providing limiting values 
in our analysis. In the first scenario, we only included 
the most abundant nucleotide at each position in each 
patient (consensus approach). The IC values computed 
in this way would be the upper limit of conservation. 
In the second scenario, we included all variants in 
the haplotypes from each patient that were present 
at abundance greater than 0.25% (quasispecies 
approach). The IC values computed in this way would 
be the lower limit of conservation. 
Sliding window analysis was then carried out to 
locate the fragment of at least 25 nt or 10 aa (which 
corresponds to the length of a possible target for 
siRNA therapy) with the highest IC within the multiple 
alignments. This analysis uses windows of 25 nt (or 
10 aa) starting from the first position in the multiple 
alignments and moves forward in steps of 1 (nt or aa). 
For each window, the analysis computes the mean IC of 
each position within the window. In addition, the results 
are represented as sequence logos created using the R 
language package motifStack[27].
The bioinformatics methods used in this study were 
reviewed by Dr. Josep Gregori from the Liver Disease-
Viral Hepatitis Laboratory of Vall d’Hebron Hospital 
(Barcelona, Spain), CIBERehd research group, and 
Roche Diagnostics SL.
RESULTS
Analysis of the NGS sequences obtained and 
genotyping results
After applying the quality filters, 1333069 sequences 
were obtained from the 27 serum samples, yielding 
a median (IQR) of 4578 (2478-9279) sequences per 
patient.
In the region from nt 1255 to 1611 extracted from 
the 102 full-length HBV genome sequences from 
GenBank, analysis of the maximum genetic distance 
within the same genotype (data not shown) resulted 
in a sequence identity threshold of 96%. Therefore, 
for each patient, haplotypes with a sequence identity 
> 96% were clustered together and were considered 
to belong to the same HBV genotype. Results of the 
phylogenetic analysis of master sequences from each 
cluster in each patient and the 102 GenBank patterns 
are shown in Table 2. Genotype D nt haplotypes 
were the most frequent in our patients, followed by 
genotypes C, A, E, F, B, and H. None of the patients 
included showed genotype G haplotypes. Moreover, in 
14/27 cases (51.8%), some haplotypes were found 
corresponding to different genotypes than those 
previously identified by Sanger sequencing, thus 
yielding a complex mixture of genotypic variants.
Conservation of the HBX nucleotide sequence in the 
region of interest
The region of interest was studied in multiple nt align-
ments of the entire quasispecies in order to highlight 
the most highly conserved regions. Sliding windows 
analysis was implemented in two scenarios: using the 
consensus approach (n = 27 sequences) and using the 
quasispecies approach (n = 720 sequences). Of note, the 
relative frequency of each haplotype was not considered 
in the multiple alignments, so that the conservation 
results would not be influenced by haplotype fitness. 
As no differences were seen when the analyses by the 
2 approaches were superimposed (2 highly conserved 
regions with a mean IC near 2 bits were observed in 
both; Figure 2), the results reported below all refer to the 
analysis in the quasispecies scenario. 
The first hyper-conserved region identified was 
between nt 1255 and 1286 (23 nt in length) (Figure 
3A). Most of the nucleotide positions showed high 
conservation, yielding IC values near 2 bits (100% 
maximum conservation), with the exception of position 
1272 which showed an IC between 1.6 and 1.8 bits 
(80%-90% maximum conservation) and positions 
1258 and 1284, with an IC between 1.4 and 1.6 bits 
(70%-80% maximum conservation). 
The second hyper-conserved region consisted of 3 
conserved nt fragments (1519-1543, 1545-1573, and 
1575-1603: 25, 29, and 29 nt in length, respectively) 
ICj (nt) = log2(4)-∑pij log2(pij)
4
i=1
ICj (aa) = log2(20)-∑pij log2(pij)
20
i=1
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spanning a region between nt 1519 and 1603 (85 nt). 
Five of these 85 nt positions (5.9%) showed an IC 
below 1.8 bits: positions 1527, 1557, 1589, and 1602 
between 1.6 and 1.8 bits, and position 1524 between 1.4 
and 1.6 bits (Figure 2B). 
Conservation of the HBx amino acid sequence
To further confirm the nt conservation found, we also 
analyzed aa conservation in the same 2 scenarios 
considered for nt variants (n = 27 sequences for 
the consensus and n = 330 for the quasispecies 
approach). As was seen with the nt sequences, there 
were no difference when the 2 analyses (quasispecies 
vs consensus) were superimposed (Figure 4), which 
highlighted a single highly conserved region. Again, 
the results reported refer to the analysis using the 
quasispecies approach. 
One highly conserved region was identified between 
aa 63 and 76 (13 aa), which included a portion of a 
Kunitz-like domain (Figure 5). All aa showed conservation 
near 4 bits (100% maximum conservation). This region 
in the HBx protein corresponded to the hyper-conserved 
nt sequence between positions 1563 and 1602. The first 
hyper-conserved nt region observed (nt 1255-1286) was 
not taken into account in this analysis, as it corresponded 
to a non-coding region and therefore, was not translated 
into aa. 
DISCUSSION
Although classic nucleotide analogue-based therapies 
can effectively control HBV infection, eradication of the 
virus is not achieved because of persistence of the viral 
minichromosome, cccDNA. Furthermore, even though 
HBV replication can be inhibited by drug treatment, 
production of viral antigens may be maintained, and this 
could lead to progression of the disease[29]. To overcome 
this challenge, new therapeutic approaches are needed, 
and gene therapy has emerged as an interesting option. 
Ramanan et al[30] proposed a gene therapy based on 
CRISPR/Cas9 to specifically target a conserved region in 
HBV cccDNA. These authors reported an anti-HBV effect 
both in vitro and in vivo, together with inhibition of de 
novo infection in HepG2-hNTCP cells. However, in HBV 
infection, the viral genome may be inserted in the host 
genome. Hence, it is possible that a molecular scissors 
strategy, such as the CRISPR/Cas9 approach, might 
imply a risk of affecting the host genome in the regions 
of viral genome insertion.
With the siRNA approach, viral replication could be 
hampered and disease progression limited by direct 
interference with the viral messengers. As has been 
seen in both cell and mouse models[12,31-33], this inter-
fering RNA regulates the expression of specific viral 
genes by promoting cleavage of targeted mRNAs, thus 
Table 2  Results of genotyping of nucleotide haplotypes obtained in each patient, extracted by next-generation sequencing based on 
ultra-deep pyrosequencing analysis %
Patient A B C D E F H
1 0 0 0 0 100 0 0
2 0 0 100 0 0 0 0
3 7.1 0 0 92.9 0 0 0
4 0 0 0 100 0 0 0
5 0 0 0 100 0 0 0
6 1.7 0 0 98.3 0 0 0
7 0 0 0.3 51.3 0 48.4 0
8 7.1 0 0 92.9 0 0 0
9 0 0 0.3 7 0 92.7 0
10 0.9 0 0 50.9 0 0 48.2
11 0 0 0.3 7 0 92.7 0
12 95.1 0 4.4 0.5 0 0 0
13 0 0 100 0 0 0 0
14 46.6 0 8.2 33.2 0 12 0
15 89.7 0 4.4 8 0 1.5 0
16 0 0 0 100 0 0 0
17 0 0 0 100 0 0 0
18 0 0 0 0 100 0 0
19 0 0 95.3 3,6 0.9 0 0
20 100 0 0 0 0 0 0
21 0 99.6 0.4 0 0 0 0
22 0 0 100 0 0 0 0
23 0 0 87.8 12.2 0 0 0
24 0 0 100 0 0 0 0
25 97.9 0 0 2.1 0 0 0
26 0 0 100 0 0 0 0
27 0 0 0 100 0 0 0
%A to %H indicates the percentage of nucleotide haplotypes from each patient, classified as HBV genotype A, B, C, D, E, F or H. HBV: Hepatitis B virus.
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inhibiting HBV replication. Specifically, siRNA promotes 
target mRNA cleavage in a sequence-specific manner 
through the RNA-induced silencing complex (RISC)[34]. 
Definition of an extremely conserved region in an 
optimal HBV genomic region, such as the HBX gene, 
could be very useful for siRNA-based gene therapy 
strategies, and some authors have investigated this 
concept. In a recent study using predictive software, 
Thongthae et al[33] estimated potential siRNA target sites 
in the HBX gene (positions: 1317-1337, 1357-1377, 
and 1644-1664) from an HBV genotype A sequence. 
These were later tested in vitro, and a reduction in HBV 
expression was observed. In another effort, the Arbutus 
Biopharma Corporation recently published a phase-two 
study in this line. An siRNA was used as treatment for 
patients with chronic HBV infection, and the preliminary 
data indicated that the therapy was well tolerated and 
led to a significant reduction in HBsAg levels[35,36]. 
HBX is located near the co-terminal 3’ end of all the 
HBV mRNAs, which implies that interference at this level 
could abrogate the production of all the viral antigens. 
In addition, the HBX gene encodes a protein, HBx, 
which plays a key role in the HBV viral cycle. However, 
previous data reported by our group[37] and supported 
in other studies[17,38-40] have described considerable 
variability in the HBx transactivating C-terminal domain 
(encoded by the 3’ end of the gene), with multiple 
insertions and deletions. Because of this variability, this 
region would not be considered an appropriate gene 
therapy target. 
In light of the importance of the HBx protein for viral 
replication, it would be reasonable to posit that the gene 
encoding this protein would have a conserved region. 
On that basis and after excluding the 3’ end region, we 
focused our study on the 5’ end region of HBX and its 
upstream non-coding region (nt 1255-1611). For a gene 
therapy to be effective in a broad range of conditions, 
the target sequence should remain conserved in a wide 
spectrum of clinical and virological situations. Hence, 
we analyzed samples from a heterogeneous group of 
27 HBV-infected patients (in different clinical stages 
of HBV infection and with different viral genotypes) to 
seek a conserved target sequence over this spectrum. 
Two hyper-conserved regions were found. The first 
was located between nucleotides 1255 and 1286 in the 
non-coding region. Of note, HBX transcripts initiate at 
several different sites (between nt 1250-1350)[41], which 
means that this conserved region might be not present 
in all of them, but would likely be present in the other 
viral transcripts. The second hyper-conserved region 
was located between nucleotides 1519 and 1603, within 
the coding region. 
Conserved regions in this portion of the HBV gene 
have been reported previously. Karinova et al[42] observed 
two conserved regions in the S and X ORF of the HBV 
genotype A genome. These authors found that a 
CRISPR/Cas9 molecular scissor directed to this conserved 
region in HBX was able to modify both episomal cccDNA 
and chromosomally-integrated HBV DNA in reporter cell 
lines, thereby interfering with HBV replication and with de 
novo infection of hepatoma cell lines. In addition, with the 
use of predictive software, Thongthae et al[33] estimated 
some potential siRNA targets in the HBX gene (including 
the non-coding region identified here) in a single viral 
sequence, and reported the efficacy of this approach 
in an in vitro study. The value of the present study is 
that conservation of the regions examined was directly 
substantiated by sequencing analysis of patient samples, 
taking into account different HBV genotypes and 
different clinical stages of the infection. Furthermore, the 
nucleotide conservation documented here was supported 
by detection of a conserved region in the HBx protein 
sequence between aa 63 and 76, which is encoded by nt 
1563-1602 (within the second hyper-conserved region). 
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Figure 2  Sliding window analysis of the nucleotide region of interest in the hepatitis B virus X gene (nt 1255-1611). Each point on the graph is the result of 
the mean information content (IC, bits) of the windows 25-nt in size, with displacement between them in 1-nt steps. The purple line represents the mean IC from the 
multiple alignments of all haplotypes (in abundance > 0.25%) in the quasispecies (QS) of all patients (n = 720), whereas the blue line shows the mean IC obtained 
from the multiple alignments of the consensus obtained for each patient (n = 27).
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Of note, this fragment includes some aa from one of the 
HBx Kunitz-like domains (aa 58-70)[43], which are able to 
inhibit the function of cellular degrading enzymes, such 
as proteases[44]. This suggests that this portion of the 
HBx protein may be conserved to preserve the integrity 
of the protein, protecting it from undesired degradation. 
As a limitation of the study, we should mention the 
relatively small sample size. From the initial group of 
46 well-characterized treatment-naïve CHB patients 
available, only those with viremia levels high enough to 
amplify the HBV genome region of interest by our PCR 
technique could be included. Furthermore, we wished to 
1   2    3    4    5    6   7    8    9   10       12        14       16        18        20        22       24        26       28
Position
1255:1283
2
1
0
Bi
ts
1     2    3     4     5    6     7     8    9    10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25
Position
1262:1286
2
1
0
Bi
ts
1     2    3     4     5    6     7     8    9    10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25
Position
1519:1543
2
1
0
Bi
ts
1    2    3    4    5    6   7    8    9   10       12        14       16        18        20        22       24        26        28
Position
1545:1573
2
1
0
Bi
ts
1    2    3    4    5    6   7    8    9   10       12        14       16        18        20        22       24        26        28
Position
1575:1603
2
1
0
Bi
ts
A
B
Figure 3  Representation by sequence logos of the information content of the most conserved regions detected in the multiple alignment of all nucleotide 
haplotypes obtained (quasispecies), nts 1255-1286 and nts 1519-1603. The relative sizes of the letters in each stack of nt sequence logos indicate their relative 
frequencies at each position within the multiple alignments of nt haplotypes. The total height of each stack of letters depicts the IC of each nt position, measured in 
bits (Y-axis): 0 bits being the minimum and 2, the maximum conservation. Nucleotide positions with an IC between 1.6 and 1.8 (80%-90% of maximum conservation) 
are indicated by light blue circles and those with an IC between 1.4 and 1.6 bits (70%-80% of maximum conservation) by pink circles. IC: Information content.
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have a representation of various clinical stages of HBV 
infection and most HBV genotypes (A to F and H), which 
yielded a sample of 27 patients. Larger samples should 
be analyzed in future studies to confirm conservation 
of the regions investigated. We also have to point out 
that the NGS technology used in this study (GS-Junior 
platform, 454/Roche) has been discontinued by the 
supplier; nonetheless, the protocol described here can 
be adapted to currently available platforms, such as the 
Illumina MiSeq (San Diego, United States). Finally, in 
vitro functional studies should be performed to test the 
potential usefulness of the 2 hyper-conserved domains 
described here as targets for siRNA-based antiviral gene 
therapy.
In summary, this study, performed in serum samples 
from HBV patients infected by different viral genotypes 
and in different clinical stages, identified regions in the 
HBX gene with high levels of conservation in all these 
circumstances. We found 2 hyper-conserved regions, the 
first in the non-coding region of HBX transcripts, and the 
second in the HBX coding region, which was conserved at 
both the nt and aa level. These hyper-conserved regions 
could be candidates for targeted gene therapies such as 
the siRNA approach. Of particular interest, because of the 
co-terminal localization of the HBX gene, a siRNA system 
designed to target these regions could interfere with 
expression of all the HBV viral transcripts. 
ARTICLE HIGHLIGHTS
Research background
Hepatitis B virus (HBV) infection can be controlled with current treatments, 
but cure is not achieved due to persistence of covalently closed circular DNA 
(cccDNA) in the nuclei of infected hepatocytes. This minichromosome forms a 
viral reservoir that is a source of residual viral replication and expression of viral 
proteins; thus, it has a key role in liver disease progression. To surmount this 
circumstance, new anti-HBV therapeutic approaches are under development, 
with gene therapy being a promising option. Among these approaches, small 
interference RNA (siRNA) can be used to silence specific genes at the post-
transcriptional level through a sequence-specific interaction with target mRNAs, 
resulting in inhibition of viral protein expression. Among all the HBV proteins, 
Hepatitis B X protein (HBx), coded by the HBV X gene (HBX), is a determining 
factor in the infection. It regulates cccDNA expression and interacts with several 
cellular pathways, facilitating liver disease progression. Of particular note, 
because of its location near the co-terminal 3’ end, all HBV transcripts include 
the HBX sequence. Hence, it could be a valuable target for a hypothetical 
curative treatment based on gene therapy. In this sense, identification of hyper-
conserved regions within HBX is needed to define a new gene therapy system 
that would be effective whatever the patient’s clinical stage or HBV genotype.
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Figure 4  Sliding window of the coded the core and X protein amino acid sequence (aa 1-79). Each point on the graph is the result of the mean information 
content (IC, bits) between windows of 10-aa size with displacement between them in 1-aa steps. The purple line represents the mean IC from the multiple alignments 
of all haplotypes (in abundance > 0.25%) in the quasispecies (QS) of all patients (n = 330), whereas the blue line shows the mean IC obtained from the multiple 
alignments of the consensus obtained for each patient (n = 27).
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haplotypes obtained. The total height of each stack of letters depicts the IC of each aa position, measured in bits (Y-axis): 0 bits being the minimum and 4.32 bits the 
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Research motivation
Although antiviral therapy can suppress viral replication, the risk of liver disease 
progression and development of hepatocellular carcinoma (HCC) remains due 
to cccDNA-related expression of viral antigens. Interference with expression 
of the viral proteins could be helpful to limit progression of the disease, and 
siRNAs would be valid tools in this sense. To design an effective siRNA, an 
appropriate target must be found. The HBX sequence is included in all the 
viral transcripts due to its co-terminal localization in the viral genome. siRNAs 
targeting hyper-conserved regions of this gene would interfere with expression 
of all the viral proteins. Furthermore, as these regions are conserved in the 
spectrum of clinical disease phases and viral genotypes, it would be a valid 
therapeutic approach for a wide range of situations. This could profoundly limit 
the risk of HCC, particularly in patients with low viremia due to antiretroviral 
efficacy.
Research objectives 
Considering the essential role of HBx in viral infection and its potential utility as 
target for gene therapy, the aim of this study was to identify hyper-conserved 
regions within the HBV genome encompassing the HBX 5’ coding region and 
the upstream non-coding region (included in all HBV transcripts) in samples 
from HBV-infected patients in various clinical stages and with different viral 
genotypes. The regions identified might be feasible targets for a gene therapy 
able to inhibit viral protein expression in a wide spectrum of clinical and 
virological circumstances, thus limiting liver disease progression and the risk of 
HCC.
Research methods
The study included 27 treatment-naïve chronic hepatitis B monoinfected 
patients in different clinical stages and with several HBV genotypes (from 
A-F and H). A serum sample from each patient with viremia > 3.5 log IU/mL 
was analyzed. The HBX 5’ end region [nucleotide (nt) 1255-1611] was PCR-
amplified and later analyzed using next-generation sequencing (NGS). 
The sequences (reads) obtained after sequencing underwent an in-house 
bioinformatics filtering procedure, and haplotypes with a relative frequency 
≥ 0.25% were maintained in the analysis. Haplotypes were genotyped by 
discriminant analysis with the same regions extracted from the 102 full-length 
patterns. Conservation of the quasispecies sequences was determined by 
calculating the information content (IC), based on Shannon’s uncertainty, of 
each position in a multiple alignment of all different sequences found in the 
patients. Sliding window analysis was then carried out to locate the fragment 
of at least 25 nt or 10 aa (which corresponds to the length of a possible target 
for siRNA therapy) with the highest IC within the multiple alignments, moving 
forward in steps of 1 (nt or aa). This method enables detection of conserved 
regions within the 5’ HBX gene by directly analyzing the viral quasispecies 
obtained with NGS. 
Research results
After applying the quality filter, 1333069 haplotype sequences were obtained. 
Genotyping analysis highlighted a complex mixture of HBV genotypes. By 
studying the nt conservation, we identified two hyper-conserved nucleotide 
regions in HBX. The first one, between nt 1255 and 1286, corresponded to 
a non-coding region, whereas the second one, consisting of 3 conserved 
fragments (spanning an overall portion between 1519 and 1603), coincided 
with a coding region. Of note, the fragment between nt 1563 and 1602 was also 
conserved at the amino acid level, identifying a region between residues 63 and 
76, which included a portion of a Kunitz-like domain. These results highlight 
new potential targets for gene therapy, mainly based on siRNA. Of note, in vitro 
and in vivo functional studies of the specific siRNAs should be performed to test 
their potential usefulness for therapy.
Research conclusions
Gene therapy represents a highly promising therapeutic tool to achieve a 
cure against HBV infection. Several sequence-specific treatment systems are 
currently in development, and identification of conserved sequences would 
provide useful therapeutic targets. Detection of a target present in all the 
clinical disease stages and HBV genotypes could lead to development of a 
therapy that would be effective in a wide range of situations. Considering the 
key role of HBx in viral infection and disease progression, we focused the study 
on analyzing conservation of the HBX gene. Of note, considering the high 
variability previously observed in the 3’end of HBX, we speculated that the 5’
end could be a better subject for study. Moreover, thanks to the co-terminality 
of this viral gene, a siRNA targeting this gene could interfere with all the viral 
transcripts. Here, we investigated conservation of a portion of the HBV genome 
encompassing the HBX 5’ coding region and upstream non-coding region, both 
of which are included in all HBV transcripts. By NGS analysis, we identified 
two hyper-conserved regions in our region of interest in serum samples from 
HBV patients with different clinical and virological characteristics. This new 
therapeutic tool could have relevant applicability in clinical practice. Together 
with inhibition of the expression of one of the main viral proteins involved in 
HBV replication and disease progression, it could block the expression of the 
other viral antigens, thus profoundly interfering with disease evolution and the 
appearance of HCC. Furthermore, the NGS method developed here could be 
used to find other hyper-conserved regions within the HBV genome that could 
be potential targets for gene therapy based on siRNA. 
Research perspectives
This study describes a method that can be used to find other conserved 
sequences in the HBV genome, making it a starting point in the search for other 
possible targets for gene therapy. Here, the hyper-conserved regions were 
found by directly analyzing the viral quasispecies sequences obtained using 
NGS. These regions can then be used to produce siRNA molecules for in vitro 
and in vivo testing of antiviral activity.
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